| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/22/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/22/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/13/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/06/2023 |
4
| HENSON HEIDI (Director) has filed a Form 4 on Perspective Therapeutics, Inc.|
Txns:
| Granted 470,000 options to buy
@ $0.55, valued at
$258.5k
Granted 230,000 options to buy
@ $0.55, valued at
$126.5k
|
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Appointed a new director |
| 05/01/2023 |
10-KT
| Form 10-KT - Transition reports [Rule 13a-10 or 15d-10]: |
| 04/21/2023 |
8-K/A
| Quarterly results |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Williamson Robert F III (Director) has filed a Form 4 on Perspective Therapeutics, Inc.|
Txns:
| Granted 470,000 options to buy
@ $0.38, valued at
$178.6k
Granted 230,000 options to buy
@ $0.38, valued at
$87.4k
|
|
| 03/17/2023 |
3
| Williamson Robert F III (Director) has filed a Form 3 on Perspective Therapeutics, Inc. |
| 03/15/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 02/23/2023 |
4
| Morich Frank (Director) has filed a Form 4 on Perspective Therapeutics, Inc.|
Txns:
| Granted 470,000 options to buy
@ $0.38, valued at
$178.6k
Granted 230,000 options to buy
@ $0.38, valued at
$87.4k
|
|
| 02/23/2023 |
4
| Woods Lori A (Director) has filed a Form 4 on Perspective Therapeutics, Inc.|
Txns:
| Granted 470,000 options to buy
@ $0.38, valued at
$178.6k
Granted 230,000 options to buy
@ $0.38, valued at
$87.4k
|
|
| 02/23/2023 |
4
| McCormick Michael W (Director) has filed a Form 4 on Perspective Therapeutics, Inc.|
Txns:
| Granted 470,000 options to buy
@ $0.38, valued at
$178.6k
Granted 230,000 options to buy
@ $0.38, valued at
$87.4k
|
|
| 02/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/06/2023 |
8-K
| Appointed a new director |
| 01/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &... |
| 01/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &...|
Docs:
|
"Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023 RICHLAND, WASHINGTON – January 12, 2023 – Isoray, Inc. , a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholders is being adjourned until January 27th, 2023, to provide stockholders who have not yet voted with additional time to vote on Proposal 1, approval of an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc. The Board of..." |
|
| 12/14/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|